Q4 2024 Management View CEO Paula Ragan highlighted 2024 as a transformative year for X4 Pharmaceuticals, with the U.S. approval and launch of XOLREMDI (mavorixafor) for WHIM syndrome, a rare ...

To determine if you have neutropenia, your provider will review the test results to determine your absolute neutrophil count ...

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line ...

The ANC testing is part of labeling, as the drug poses a risk for neutropenia. The REMS required that physicians and pharmacists be certified to prescribe and dispense the drug, which was ...

FDA still recommends that prescribers monitor patients’ ANC according to the monitoring frequencies described in the prescribing information. Information about severe neutropenia will remain in the ...

Prior to pharmacies dispensing clozapine, the FDA required patients to obtain and report a baseline absolute neutrophil count (ANC) blood test. In order to continue treatment, the ANC was to be ...

As part of the overhaul, prescribers will no longer be required to report the results of absolute neutrophil count (ANC) blood tests before pharmacies dispense clozapine to patients. However ...

Late-onset neutropenia (LON) is a common late adverse event after rituximab treatment. LON is defined as an unexplained absolute neutrophil count of ≤1.5 ×10 9 /l, starting from 4 weeks after ...

Neutropenia in individuals with a congenital defect or patients with cancer who are undergoing chemotherapy is generally treated with granulocyte colony-stimulating factor (G-CSF) to restore ...